2MUS

HADDOCK calculated model of LIN5001 bound to the HET-s amyloid


Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 200 
  • Conformers Submitted: 
  • Selection Criteria: target function 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Structure-based drug design identifies polythiophenes as antiprion compounds.

Herrmann, U.S.Schutz, A.K.Shirani, H.Huang, D.Saban, D.Nuvolone, M.Li, B.Ballmer, B.Aslund, A.K.Mason, J.J.Rushing, E.Budka, H.Nystrom, S.Hammarstrom, P.Bockmann, A.Caflisch, A.Meier, B.H.Nilsson, K.P.Hornemann, S.Aguzzi, A.

(2015) Sci Transl Med 7: 299ra123-299ra123

  • DOI: 10.1126/scitranslmed.aab1923

  • PubMed Abstract: 
  • Prions cause transmissible spongiform encephalopathies for which no treatment exists. Prions consist of PrP(Sc), a misfolded and aggregated form of the cellular prion protein (PrP(C)). We explore the antiprion properties of luminescent conjugated pol ...

    Prions cause transmissible spongiform encephalopathies for which no treatment exists. Prions consist of PrP(Sc), a misfolded and aggregated form of the cellular prion protein (PrP(C)). We explore the antiprion properties of luminescent conjugated polythiophenes (LCPs) that bind and stabilize ordered protein aggregates. By administering a library of structurally diverse LCPs to the brains of prion-infected mice via osmotic minipumps, we found that antiprion activity required a minimum of five thiophene rings bearing regularly spaced carboxyl side groups. Solid-state nuclear magnetic resonance analyses and molecular dynamics simulations revealed that anionic side chains interacted with complementary, regularly spaced cationic amyloid residues of model prions. These findings allowed us to extract structural rules governing the interaction between LCPs and protein aggregates, which we then used to design a new set of LCPs with optimized binding. The new set of LCPs showed robust prophylactic and therapeutic potency in prion-infected mice, with the lead compound extending survival by >80% and showing activity against both mouse and hamster prions as well as efficacy upon intraperitoneal administration into mice. These results demonstrate the feasibility of targeted chemical design of compounds that may be useful for treating diseases of aberrant protein aggregation such as prion disease.


    Related Citations: 
    • 13C, 15N resonance assignment of parts of the HET-s prion protein in its amyloid form.
      Siemer, A.B.,Ritter, C.,Steinmetz, M.O.,Ernst, M.,Riek, R.,Meier, B.H.
      (2006) J.Biomol.Nmr 34: 75
    • Amyloid fibrils of the HET-s(218-289) prion form a beta solenoid with a triangular hydrophobic core.
      Wasmer, C.,Lange, A.,Van Melckebeke, H.,Siemer, A.B.,Riek, R.,Meier, B.H.
      (2008) Science 319: 1523


    Organizational Affiliation

    Institute of Neuropathology, University Hospital of Zürich, University of Zürich, 8091 Zürich, Switzerland.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Heterokaryon incompatibility protein s
A, B, C, D, E
79Podospora anserinaGene Names: het-s (small s)
Find proteins for Q03689 (Podospora anserina)
Go to UniProtKB:  Q03689
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
3LS
Query on 3LS

Download SDF File 
Download CCD File 
B
3''',4'-bis(carboxymethyl)-2,2':5',2'':5'',2''':5''',2''''-quinquethiophene-5,5''''-dicarboxylic acid
C26 H16 O8 S5
SZFMXSCJFCPHEZ-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 200 
  • Conformers Submitted: 
  • Selection Criteria: target function 

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Revision History 

  • Version 1.0: 2017-02-01
    Type: Initial release
  • Version 1.1: 2017-02-22
    Type: Database references